Education
- 2005 – 2018: Medical oncologist at Fondazione IRCCS “Istituto Nazionale Tumori”, Milano, Italy
- 2005: Postgraduate certificate in Clinical Oncologia (70/70 cum laude) at University, Milano, Italy
- 2001: Medical Degree (cum laude) at University, Milano, Italy
Academic Appointments
- 2023 – present: Associate Professor of Medical Oncology and Head of the Head and Neck Cancer Unit;
- 2023 – present: Director of the Head and Neck, Skin and GI Cancer
- 2019 – 2023: Associate Professor of Medical Oncology at University of Brescia
Awards and Honors
- 2016: Best project in Head and Neck multidisciplinary management, AIOM
- 2011: Clinical Young Researcher Award, Fondazione Berlucchi
- 2009: Clinical Young Researcher Award, Fondazione Istituto Nazionale dei Tumori
He is involved in all institutional research activities on head and neck cancer, from translational research (gene expression, next generation sequencing) to assessment of quality of life and value-based medicine. He is particularly dedicated to rare cancer among head and neck ones (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer). He has strong experience with medical treatment of non-melanoma skin cancer, designing and conducting trials with targeted therapy and immunotherapy. He has a strong commitment to supportive care, specifically for what concerns mucositis induced by cancer therapies.
He collaborates to the Italian Network on Rare Tumors, a collaborative effort among Italian cancer centers, which tries to exploit distant patient sharing to improve quality of care and diminish health migration for rare solid cancers. He is the Principal Investigator and co-investigator of several Italian and International trial on Head and Neck cancer and non-melanoma skin cancer.
- Elad S., Cheng K. K. F., Lalla R. V., Yarom N., Hong C., Logan R. M., Bowen J., Gibson R., Saunders D. P., Zadik Y., Ariyawardana A., Correa M. E., Ranna V., Bossi P.; e altri membri del Mucositis Guidelines Leadership Group (MASCC/ISOO); MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy; Cancer, 2020. 26(19):4423-4431
- Bossi P., Chan A. T. C., Licitra L., Trama A., Orlandi E., Hui E. P., Halámková J., Mattheis S., Baujat B., Hardillo J., Smeele L., van Herpen C., Castro A., Machiels J.-P.; ESMO Guidelines Committee; Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up; Annals of Oncology, 2021. 32(4):452-465
- Rischin D., Porceddu S., Day F., Brungs D. P., Christie H., Jackson J. E., Stein B. N., Su Y. B., Ladwa R., Adams G., Bowyer S. E., Otty Z., Yamazaki N., Bossi P., Challapalli A., Hauschild A., Lim A. M., Patel V. A., Walker J. L., De Liz Vassen Schurmann M., Queirolo P., Cañueto J., Da Silva F. A. F., Stratigos A., Guminski A., Lin C., Damian F., Flatz L., Taylor A. E., Carr D. R., Harris S., Kirtbaya D., Quereux G., Rutkowski P., Basset-Seguin N., Khushalani N. I., Robert C., Ju H., Joseph C., Bansal S., Chen C.-I., Seebach F., Yoo S.-Y., Lowy I., Goncalves P., Fury M. G.; Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma; New England Journal of Medicine, 2025. 393(8):774-785
- Ferrari M., Mularoni F., Smussi D., Gaudioso P., Bonomo P., Friborg J., Ghi M. G., Gregoire V., Harrington K., Hunter K., Maroldi R., Martino R., Mesia R., Peretti G., Psyrri A., Schindler A., Succo G., Szturz P., Vilaseca I., Nicolai P., Bossi P., Consensus Group for Laryngeal Preservation; International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer; Lancet Oncology, 2025. 26(5):e264-e281
- Saini K. S., Somara S., Ko H. C., Thatai P., Quintana A., Wallen Z. D., Green M. F., Mehrotra R., McGuigan S., Pang L., Das S., Yadav K., Neric D., Cantini L., Joshi C., Iwamoto K., Dubbewar S., Vidal L., Chico I., Severson E., Lorini L., Badve S., Bossi P.; Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy; Frontiers in Oncology,2024. 14:1473706